Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes
Open Access
- 18 November 2025
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 40 (1) , 37-46
Abstract
Diverse haematological neoplasms are driven by tyrosine kinase (TK) fusion genes formed by recurrent or non-recurrent genomic rearrangements. The resulting chimeric proteins often present excellent targets for treatment with kinase inhibitors, and the fusion transcripts or genomic junctions can be used as specific targets for molecular monitoring. Whilst the TK genes involved are generally well characterised (e.g. ABL1, PDGFRA, FGFR1 ), the fusion partners are very diverse, presenting a challenge for detection and characterisation of these structural variants (SV) using current diagnostic methods. We assessed the ability of targeted nanopore sequencing using adaptive sampling to detect fusion genes in myeloid neoplasms. We sequenced genomic DNA from patients ( n = 20) with a known or suspected TK gene fusion and identified rearrangements in 18 cases, including all cases with a known TK fusion, typical and atypical BCR::ABL1 rearrangements, an 843Kb deletion causing a FIP1L1::PDGFRA fusion, novel AGAP2::PDGFRB and NFIA::PDGFRB fusions, and a complex CCDC88C::PDGFRB rearrangement with multiple translocation events. The approach was fast (<72 h/sample from DNA to result), flexible with minimal hands-on laboratory time, and provided accurate, patient-specific characterisation of genomic breakpoints.Keywords
Funding Information
- European Treatment and Outcome Study
This publication has 49 references indexed in Scilit:
- 75. Novel complex translocation involving PDGFRA::PRKG2, in a myeloid neoplasm with basophilia sample by OGMCancer Genetics, 2023
- Epidemiology, clinical picture and long‐term outcomes ofFIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patientsAmerican Journal of Hematology, 2020
- Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1‐JAK2, BCR‐JAK2 and ETV6‐ABL1 fusion genesAmerican Journal of Hematology, 2020
- A Nanopore Sequencing–Based Assay for Rapid Detection of Gene FusionsThe Journal of Molecular Diagnostics, 2019
- A multimodality work‐up of patients with HypereosinophiliaAmerican Journal of Hematology, 2018
- Ankyrin repeats as a dimerization moduleBiochemical and Biophysical Research Communications, 2018
- Natural course and biology of CMLAnnals of Hematology, 2015
- Sole abnormalities of chromosome 7 in myeloid malignancies: Spectrum, histopathologic correlates, and prognostic implicationsAmerican Journal of Hematology, 2012
- Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctionsLeukemia, 2008
- Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disordersCancer Genetics and Cytogenetics, 2008